Other languages ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
5.24 ^USD	+2.54%		-15.07%	+4.38%

Mar. 26	North American Morning Briefing : Markets Steady -2-	DJ
Mar. 25	Piper Sandler Adjusts Price Target on ImmunityBio to $5 From $4, Maintains Neutral Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ImmunityBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19
ImmunityBio Announces Data from A Phase 1 Pilot Study	Mar. 05
ImmunityBio Says Cancer Vaccine Trial Moving to Controlled Phase	Feb. 21
ImmunityBio, Inc. Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial	Feb. 21
Immunitybio, Inc. Announces Findings from Patient-Reported Outcomes of Participants in the Phase 2/3 Quilt 3.032 Study of N-803 Plus BCG	Feb. 05
US Equity Markets Close Lower Tuesday Ahead of Fed Meeting Minutes	Jan. 02
Sector Update: Health Care Stocks Gain Late Afternoon	Jan. 02
Sector Update: Health Care Stocks Rise Tuesday Afternoon	Jan. 02
ImmunityBio Secures $320 Million Investment From Oberland Capital	Jan. 02
Sector Update: Health Care	Jan. 02
Top Stories at Midday: US Construction Spending Up 0.4% in November; Avangrid-PNM Resources Deal Terminated; Terreno Realty Sells California Property for $15.9 Million; ImmunityBio Secures $320 Million Investment	Jan. 02
ImmunityBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
ImmunityBio, Inc. Announces First Data for Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-Tumor Activity	Nov. 07
Sector Update: Health Care Stocks Softer Thursday Afternoon	23-10-26
ImmunityBio Shares Rise After FDA Accepted Resubmitted Biologics License Application for N-803 Plus BCG	23-10-26
ImmunityBio Says FDA Accepted Resubmitted Biologics License Application for N-803 Plus BCG	23-10-26
ImmunityBio, Inc. Announces U.S. Food and Drug Administration Accepts its BLA Resubmission as Complete and Sets New PDUFA Date	23-10-26
Sector Update: Health Care Stocks Softer Late Afternoon	23-10-23
Sector Update: Health Care Stocks Mixed in Monday Afternoon Trading	23-10-23
ImmunityBio Resubmits Biologics License Application for Bladder Cancer Combination Therapy	23-10-23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Other languages

Filters